Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free NKTR Stock Alerts

Nektar Therapeutics (NKTR) Competitors

Nektar Therapeutics logo
$56.23 -0.39 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$54.72 -1.51 (-2.69%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NKTR vs. CORT, SUPN, PRGO, PCRX, and OMER

Should you buy Nektar Therapeutics stock or one of its competitors? MarketBeat compares Nektar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nektar Therapeutics include Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.

How does Nektar Therapeutics compare to Corcept Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Nektar Therapeutics presently has a consensus target price of $149.63, indicating a potential upside of 166.09%. Corcept Therapeutics has a consensus target price of $88.83, indicating a potential upside of 14.64%. Given Nektar Therapeutics' higher probable upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Corcept Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75

Corcept Therapeutics has a net margin of 6.14% compared to Nektar Therapeutics' net margin of -284.18%. Corcept Therapeutics' return on equity of 7.40% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics-284.18% -85.40% -39.99%
Corcept Therapeutics 6.14%7.40%5.76%

Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 8 more articles in the media than Nektar Therapeutics. MarketBeat recorded 14 mentions for Corcept Therapeutics and 6 mentions for Nektar Therapeutics. Corcept Therapeutics' average media sentiment score of 0.75 beat Nektar Therapeutics' score of 0.68 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nektar Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
8 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$55.23M34.40-$164.08M-$8.42N/A
Corcept Therapeutics$761.41M10.93$99.65M$0.35221.40

Summary

Corcept Therapeutics beats Nektar Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Nektar Therapeutics (NASDAQ:NKTR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

75.9% of Nektar Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics-284.18% -85.40% -39.99%
Supernus Pharmaceuticals -3.74%13.07%9.66%

In the previous week, Nektar Therapeutics had 5 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Nektar Therapeutics and 1 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.89 beat Nektar Therapeutics' score of 0.68 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Nektar Therapeutics Positive
Supernus Pharmaceuticals Very Positive

Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$55.23M34.40-$164.08M-$8.42N/A
Supernus Pharmaceuticals$718.95M3.69-$38.55M-$0.51N/A

Nektar Therapeutics currently has a consensus price target of $149.63, indicating a potential upside of 166.09%. Supernus Pharmaceuticals has a consensus price target of $62.17, indicating a potential upside of 36.15%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

Nektar Therapeutics and Supernus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Perrigo?

Nektar Therapeutics (NASDAQ:NKTR) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Nektar Therapeutics presently has a consensus price target of $149.63, suggesting a potential upside of 166.09%. Perrigo has a consensus price target of $19.33, suggesting a potential upside of 73.41%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Perrigo
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Nektar Therapeutics has higher earnings, but lower revenue than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$55.23M34.40-$164.08M-$8.42N/A
Perrigo$4.25B0.36-$1.43B-$13.10N/A

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics-284.18% -85.40% -39.99%
Perrigo -43.50%9.96%3.90%

In the previous week, Perrigo had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 8 mentions for Perrigo and 6 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.68 beat Perrigo's score of -0.47 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nektar Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Perrigo
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Nektar Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Nektar Therapeutics had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Nektar Therapeutics and 4 mentions for Pacira BioSciences. Nektar Therapeutics' average media sentiment score of 0.68 beat Pacira BioSciences' score of 0.62 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nektar Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pacira BioSciences presently has a consensus target price of $29.40, suggesting a potential upside of 26.67%. Nektar Therapeutics has a consensus target price of $149.63, suggesting a potential upside of 166.09%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$726.41M1.26$7.03M$0.12193.42
Nektar Therapeutics$55.23M34.40-$164.08M-$8.42N/A

Pacira BioSciences has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences0.70% 10.24% 5.47%
Nektar Therapeutics -284.18%-85.40%-39.99%

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Omeros?

Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Nektar Therapeutics had 3 more articles in the media than Omeros. MarketBeat recorded 6 mentions for Nektar Therapeutics and 3 mentions for Omeros. Nektar Therapeutics' average media sentiment score of 0.68 beat Omeros' score of 0.38 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nektar Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Omeros
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics-284.18% -85.40% -39.99%
Omeros N/A -102.16%64.87%

Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$55.23M34.40-$164.08M-$8.42N/A
OmerosN/AN/A-$3.35M$0.7014.24

Nektar Therapeutics currently has a consensus target price of $149.63, indicating a potential upside of 166.09%. Omeros has a consensus target price of $40.33, indicating a potential upside of 304.55%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Nektar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Omeros
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.83

Nektar Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Omeros beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKTR vs. The Competition

Export
MetricNektar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.91B$2.96B$6.64B$12.06B
Dividend YieldN/A1.71%2.67%5.55%
P/E Ratio-6.6812.3720.9322.06
Price / Sales34.40287.11508.64105.22
Price / CashN/A55.7442.3656.09
Price / Book12.753.8810.476.72
Net Income-$164.08M$75.85M$3.56B$337.35M
7 Day Performance-3.98%-1.46%-1.11%-2.54%
1 Month Performance-31.33%-5.33%1.28%1.42%
1 Year Performance539.70%15.77%21.20%24.71%

Nektar Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTR
Nektar Therapeutics
2.6893 of 5 stars		$56.23
-0.7%		$149.63
+166.1%		+466.8%$1.91B$55.23MN/A220
CORT
Corcept Therapeutics
4.082 of 5 stars		$72.31
+1.6%		$88.83
+22.8%		+5.4%$7.78B$761.41M207.15300
SUPN
Supernus Pharmaceuticals
3.7232 of 5 stars		$43.59
-1.1%		$62.17
+42.6%		+34.2%$2.53B$718.95MN/A580
PRGO
Perrigo
3.5813 of 5 stars		$10.39
-0.7%		$19.33
+86.2%		-55.7%$1.44B$4.25BN/A8,100
PCRX
Pacira BioSciences
3.6352 of 5 stars		$22.23
-0.1%		$29.40
+32.3%		-12.0%$874.55M$726.41M185.22720

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel